How many cubic centimeters of platelet-rich plasma (PRP) should be injected into the knee joint?

PRP Injection Volume for Knee Joint

For knee osteoarthritis, inject 4-8 mL of platelet-rich plasma intra-articularly, with 8 mL showing superior outcomes in recent high-quality evidence.

Recommended Dosing Protocol

Based on the most recent and highest quality evidence, an 8 mL single injection of PRP provides significantly better pain relief and functional improvement compared to 4 mL 1. This 2024 prospective, triple-blind randomized trial demonstrated that patients receiving 8 mL (containing approximately 5.65 billion platelets) had:

• Significantly better improvement in all patient-reported outcomes (WOMAC, VAS, KOOS) at 6 weeks, 3 months, and 6 months (P < .001)
• 96% patient satisfaction at 6 months versus 68% with 4 mL
• Twice the absolute platelet count delivered (5.65 billion vs 2.82 billion platelets)

The study used leucocyte-depleted PRP with 3.5x concentration (final platelet concentration 706.74 × 10³/μL) 1.

Standard Practice Patterns

A 2024 scoping review analyzing 14 studies with 1,704 patients found the most common protocol was 4.357 ± 1.419 mL per injection 2. However, this represents historical practice rather than optimal dosing.

Platelet concentration matters as much as volume. A 2024 cohort study of 253 patients demonstrated that higher platelet concentrations correlate with:

• Better clinical outcomes at all time points (2,6, and 12 months)
• Lower failure rates (3.3% in high-platelet group vs 15% in low-platelet group)
• Greater improvement in KOOS Pain scores 3

Practical Administration Guidelines

Injection schedule: The most common regimen is 3 injections given 4 weeks apart 2, though the single 8 mL dose showed excellent results without repeated injections 1.

Minimum platelet threshold: Ensure platelet concentration is at least 150,000/μL in the final product 2.

Volume considerations:

• 4 mL = minimum effective dose for symptomatic relief
• 8 mL = superior outcomes with acceptable safety profile
• 5-6 mL = commonly used middle ground 4

Important Caveats

Patient selection matters: PRP shows inconsistent results in severe knee osteoarthritis (Kellgren-Lawrence grade 3-4) 5. The evidence supports use primarily in early to moderate OA (KL grades 1-2) 1.

Short-term side effects with higher volumes: The 8 mL dose caused more self-limiting pain and stiffness lasting 2-7 days (P < .001), but these resolved without intervention 1.

Guideline perspective: The 2022 AAOS guidelines acknowledge PRP has some supporting evidence (2 high-quality and 1 moderate-quality study) but note concerns about cost, safety profile, and worse outcomes in severe OA 5. Despite this cautious stance, the guideline predates the strongest evidence for 8 mL dosing.

Clinical Algorithm

1. Confirm eligibility: Early to moderate knee OA (KL grades 1-2)
2. Prepare PRP: Target 3.5x platelet concentration, leucocyte-depleted preferred
3. Volume selection:
   • First-line: 8 mL single injection (best evidence for outcomes)
   • Alternative: 4 mL if cost/availability limits volume, consider 3-dose series
4. Warn patient: Expect 2-7 days of increased pain/stiffness with 8 mL dose
5. Avoid: NSAIDs post-injection (interferes with platelet function)

The 8 mL dose represents the current evidence-based standard for maximizing clinical benefit in appropriate candidates with knee osteoarthritis 1.